The document warns that the bloc lacks an effective system to manage these crises, while structural problems persist despite recently approved measures. The situation keeps access to vital treatments, including commonly used antibiotics, for European citizens at risk, the auditors point out.

Analysts agree that the European Medicines Agency saw its role increase during the COVID-19 pandemic. However, it still lacks the legal authority to assist Member States outside of health crises.

The growing shortages have prompted several nations to stockpile stocks, a practice that exacerbates the supply imbalance due to a lack of coordination, the report highlights.

For its part, the EU pharmaceutical market is fragmented, which hinders free movement and adequate supply of products.

Most medicines are approved at the national level, and even those approved throughout the EU are not uniformly available, the source adds.

Experts believe this lack of harmonization deepens the crisis and prevents an effective collective solution to the problem.

jdt/arm/mem/am